INTRODUCTION {#sec1-1}
============

In recent years, considerable attention has been focused on the development of novel drug delivery system (NDDS). The reason for this paradigm shift is the low development cost and time required for introducing an NDDS, as compared to a new chemical entity. In the form of NDDS, an existing drug molecule can get a new life, thereby increasing its market value, competitiveness, and product and product patent life. Among the various NDDS available in the market, the oral controlled release systems hold a major portion of the market because of their ease of administration and better patient compliance.\[[@ref1]\] In the conventional oral drug delivery, which is a convenient method to achieve both local and systemic effects, there is a little or no control over drug release from dosage forms. An effective concentration at the target site can be achieved by intermittent administration of a grossly excessive dose, which results in constantly changing, unpredictable, and often sub or supra therapeutic plasma concentration, leading to marked side-effects.\[[@ref2]\]

The goal of any drug delivery is to provide a therapeutic amount of drug to the proper site in the body in order to promptly achieve and thereby to maintain the desired drug concentration during treatment. The idealized objective can be achieved by a controlled release mechanism of a poorly water-soluble drug, which easily mixes with the mixture of polymeric matrix and shows good absorption rate. The mixture of the polymeric matrix materials used in the present study has good pharmaceutical properties. However, the reported methods are not suitable for all drugs. Among the reported conventional methods different strategies have been developed. In recent years many research have already been carried out in order to design different types of matrix-type microparticles loaded with hydrophilic and lipophilic drugs using toxic solvents. The use of such solvents during formulation is of environmental concern and challenges human safety. To overcome this problem, in the present study, water has been used to prepare matrix-type microparticles by phase separation method. Moreover, these matrix-type microparticles offer double benefits. Firstly, particle size is reduced to a minimum level and secondly, the presence of insoluble polymer(s) in the matrix would modify the drug release rate by changing the matrix permeability.

Ranolazine (RNZ), a novel anti-anginal agent belonging to the group of piperizine acetamide has been widely used in the treatment of cardiovascular diseases, including arrhythmias, variant and exercise-induced angina, and myocardial infarction.\[[@ref3]\]

It has been reported that RNZ improves the myocardial oxygen balance between the supply and demand of the ischemic heart, by increase in the coronary blood flow. However, to achieve and maintain the drug concentrations within the therapeutic range, it is often obligatory to take the dosage forms several times a day . The most frequently reported side-effects (unwanted effects) occurring in more than 2% of people taking RNZ include the following: Dizziness, headache, constipation, nausea.

Oral controlled multiparticulate dosage forms such as microparticles are becoming more popular than the single-unit dosage form. Microparticles showed more reproducible drug absorption and reduced risk of local irritation at the gastrointestinal tract.

Eudragit (EU) and ethyl cellulose (EC) have been used as drug carriers to achieve controlled drug delivery for the past few decades. These polymers have gained a lot of interest owing to their versatile properties.

The present study aims to prepare RNZ microparticles using the phase separation method and to characterize the microparticles for micromeritic properties, drug loading, Fourier Transform-Infrared Spectroscopy (FT-IR), differential scanning calorimetry (DSC) and *in vitro* release studies.

MATERIALS AND METHODS {#sec1-2}
=====================

RNZ was provided as a gift sample by Zydus Cadila Healthcare Ltd., Ahmedabad. EU RLPO was provided as a gift sample from Degussa India Pvt. Ltd., Mumbai. ECL was purchased from Loba Chemie Pvt. Ltd., Mumbai. All other reagents used were of analytical grade.

Preparation of microparticles {#sec2-1}
-----------------------------

Drug-loaded microparticles were prepared by phase separation method.\[[@ref4]\] Weighed amounts of RNZ were dissolved in 70 ml of acetone and this solution was added to EU and ECL polymer blend at different ratios. Under constant stirring at 3000 rpm, 30 ml of non-solvent, purified water was added drop-wise to the drug and the polymer solution (1 ml/min). In the course of the water addition, the drug and the polymer were co-precipitated out to form microparticles. The resultant microparticles were separated by vacuum filtration and dried at room temperature for 72 h. The dried microparticles were stored in a desiccator at room temperature. Formulation chart is presented in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}.

###### 

Formulation chart of prepared RNZ-loaded microparticles from F1 to F5

![](JYPharm-3-189-g001)

###### 

Formulation chart of prepared RNZ-loaded microparticles from F6 to F10

![](JYPharm-3-189-g002)

Characterization of microparticles {#sec2-2}
----------------------------------

### Particle size analysis {#sec3-1}

The particle size was measured using a Malvern MASTERSIZER 2000 version 5.1 (Malvern, UK.) The samples of RNZ microparticles were dispersed in methanol in a ratio of 1:20 and measured at a temperature of 37°C.\[[@ref5][@ref6]\]

### Angle of repose {#sec3-2}

Fixed-funnel method was employed for determining angle of repose. The angle of repose (q) for samples was calculated using the formula,

Where 'h' is height of heap and 'r' is radius of the heap.

### Compressibility {#sec3-3}

Tapped density was determined by placing a graduated cylinder containing a known mass of powder on a mechanical tapper apparatus (Electro lab tap density tester). Carr\'s index was calculated using the formula Carr\'s index = (tapped density -- bulk density) / tapped density

Fourier transform infrared spectroscopy {#sec2-3}
---------------------------------------

Drug polymer interactions were studied by Fourier Transform-Infrared Spectroscopy ( FT-IR) spectrophotometer (Shimadzu, 8033, USA) by KBr pellet method.\[[@ref7]\] The IR spectrum of the pellet from 400 -- 4000 cm^-1^ was recorded.

Differential scanning calorimetry {#sec2-4}
---------------------------------

All dynamic differential scanning calorimetry (DSC) studies were carried out on dupont thermal analyzer with 2010 DSC module.\[[@ref8]\] The instrument was calibrated using high-purity indium metal as standard. The dynamic scans were taken in nitrogen atmosphere at the heating rate of 10°C/min.

### Scanning electron microscopy {#sec3-4}

Scanning electron microscopy (SEM) photographs were taken for the prepared microparticles with a scanning electron microscope, Joel-LV-5600, USA, at the required magnification in room temperature. The photographs were observed for morphological characteristics. Photographs were taken at the magnifications of 400×, 1500× and 3000×.\[[@ref9][@ref10]\]

### Percentage yield {#sec3-5}

The yield was determined by weighing the microparticles and then finding out the percentage yield with respect to the weight of the input materials, i.e. weight of drug and polymer mixtures used. The formula for calculation of percentage yield is as follows;

Drug loading and encapsulation efficiency {#sec2-5}
-----------------------------------------

One hundred mg of RNZ microparticles were weighed and transferred to a 100-ml volumetric flask containing pH 7.4 phosphate buffer. From this, 1 ml of solution was transferred to a 10-ml volumetric flask and diluted. Further 1 ml of this solution was diluted to 10 ml and absorbance was measured at 270 nm.\[[@ref11]\] The drug content was calculated by using the formula:

Percentage encapsulation efficiency was found out by calculating the amount of drug present in 100 mg of microparticles.

*In vitro* drug release studies {#sec2-6}
-------------------------------

The *in vitro* release of drug from the microparticles was carried out in basket-type dissolution tester USP XXIII, TDT-08L, with auto sampler containing 900 ml of dissolution media ( pH 1.2 buffer for the first 2 h and in pH 7.4 phosphate buffer for the next 10 h. The volume of the dissolution media was maintained at 900 ml with constant stirring (100 rpm) and temperature of bath was maintained at 37 ± 0.5°C. Aliquots (10 ml) of dissolution media were sampled at specified time intervals and replaced with fresh media immediately after sampling. Samples were analyzed for drug content by Ultraviolet UV visible spectroscopy (Shimadzu UV 1601).The release data obtained were fitted into various mathematical models.

Dissolution studies were carried out for all the batches of the prepared formulations (10 batches) and compared with the commercial formulation Ranexa SR 200.

Drug release kinetics {#sec2-7}
---------------------

In order to understand the mechanism and kinetics of drug release, the drug release data of the *in vitro* dissolution study was analyzed with various kinetic equations. Coefficient of correlation (r) values were calculated for the linear curves obtained by the regression analysis of the above plots.\[[@ref12]\] A differential factor (f~1~) and similarity factor (f~2~) were calculated from the dissolution data according to the following equations:

where, f~1~ -- differential factor, f~2~ -- similarity factor, n - number of time point, R~t~ -- dissolution value of the reference at time, 't' and T~t~ -- dissolution value of test formulation at time 't'. Differential factor, f~1~ was calculated by the percentage difference between the two curves at each time point and measured the relative error between the two curves. The acceptable range for differential factor f~1~ is 0-15. The similarity factor f~2~ was the logarithmic reciprocal square root transformation of the sum-squared error and is a measure of the similarity in the percentage dissolution between the reference and test products. The similarity value (f~2~) obtained from dissolution profile of the reference and test products should be in the range 50-100.

RESULTS AND DISCUSSION {#sec1-3}
======================

Ten formulations were prepared using different polymer blend ratios. The drug: Polymer ratio used in all the formulations was 1:1. Various formulation and process variables that could affect the preparation and properties of the microparticles were identified and optimized to get small, discrete, uniform, smooth-surfaced, and spherical microparticles. The formulation variables included concentration of the polymer blend and the solvent used. The process variables included the stirring speed and time.

In the first five formulations (F1-F5), the drug was dissolved in acetone and in the next five formulations (F6-F10), the drug was dispersed in dimethyl formamaide (DMF) and acetone.

An important factor that influences the size distribution of microparticles is the optimum stirring speed and time. A stirring speed of 3000 rpm and 40 min stirring time was used to obtain reproducible microparticles. It was observed that with the increase in the stirring speed from 3000-3500 rpm, there was a decrease in the average size of the microparticles and recovery yield of the microparticles. It was due to the loss of microparticles that occurred during successive filtration. When the stirring speed was lower than 3000 rpm, larger microparticles were formed. The resultant microparticles were composed of irregular masses, which were not possible to distinguish as discrete individual microparticles are shown in the [Figure 1](#F1){ref-type="fig"}.

![SEM photograph of RNZ microparticles obtained at low stirring speed](JYPharm-3-189-g007){#F1}

When the stirring time was lower than 40 min, it was observed that some amount of the dissolved mass adhered to the inner sides of the beaker, resulting in lower percentage yield. The effect of stirring time on percentage yield is presented in [Table 3](#T3){ref-type="table"}. As we increase the stirring time there will be more stirring time available which causes particle size to decrease to the extent that particle loss occurs during filtration process which reduces percent yield of microparticles.

###### 

Effect of stirring time on percentage yield of RNZ-loaded microparticles

![](JYPharm-3-189-g008)

From the above results it was observed that an optimum time of 40 min produces a good yield of microparticles. Formulation F5 showed better yield when compared to the other formulations, and results are presented in [Table 4](#T4){ref-type="table"}. Repeated batches of microparticles were prepared at an optimized rate (stirring speed and stirring time) which shows reproducibility of microparticles.

###### 

Percentage yield for RNZ-loaded microparticles

![](JYPharm-3-189-g009)

The flow property of the prepared RNZ microparticles was studied by determining the angle of repose (θ) and % compressibility index (CI). The obtained data along with related parameters are presented in [Table 5](#T5){ref-type="table"}. The values of θ ranged from 26.24 to 29.12 and the Carr index was found to be between 11.22--15.01%. These results indicated that the prepared microparticles exhibited good flow properties.

###### 

Micromeritic properties of RNZ-loaded microparticles

![](JYPharm-3-189-g010)

The values of tapped density ranged between 0.210-0.301 g/cm^3^. The density difference between the formulations was negligible and the density values of formulations were well within the acceptable limits, indicating that the prepared microparticles were non-aggregated.

The average particle size/volume mean diameter (D \[ 4, 3\]) and volume median diameters (D \[v, 0.5\]), (D \[v, 0.9\]) of the microparticle formulation of RNZ (F5) are given in [Table 6](#T6){ref-type="table"} and the particle size graphs are given in [Figure 2](#F2){ref-type="fig"}. D \[ 4, 3\] is the volume mean diameter of the microspheres whose size is being determined. D \[v, 0.50\] is the median diameter and it is the value of the particle size that divides the population into two equal halves i.e. there is 50% of distribution above this and 50% below this value. D \[v, 0.90\] is the median diameter and it is the cutoff value for the distribution, which means 90% of the distribution (particle size value) is below this value.

###### 

Particle size distribution parameters of RNZ microparticles

![](JYPharm-3-189-g011)

![Particle size distribution of formulation F5](JYPharm-3-189-g012){#F2}

RNZ pure drug and the optimized formulation were subjected for FT-IR spectroscopic analysis for compatibility studies and to ascertain whether there is any interaction between the drug and the polymers used \[[Figure 3](#F3){ref-type="fig"}\]. From the data it is clear that similar characteristic peaks with minor differences were observed in drug and formulation. Hence it appears that there is no chemical interaction between the drug and the polymer. It can be concluded that the characteristics bands of pure drugs were not affected after successful loading. In order to investigate the possible interaction between the drug and the polymers, DSC studies were carried out. RNZ exhibits a sharp endothermic peak at 124.28 corresponding to its melting point and a similar condition was also observed in the formulation confirming the stability of the drug in the formulation \[[Figure 4](#F4){ref-type="fig"}\].

![FT-IR spectra showing drug-polymer compatibility](JYPharm-3-189-g013){#F3}

![DSC comparison of pure drug and formulation F5](JYPharm-3-189-g014){#F4}

SEM photographs showed that the drug-loaded microparticles were spherical in nature (mean size of around 285.9 μm), had a smooth surface with inward dents and shrinkage due to the collapse of the wall of the microparticles. SEM photographs shown in [Figure 5](#F5){ref-type="fig"} reveal the absence of drug particles on the surface of the microparticles indicating the uniform distribution of the drug in the walls of the microparticles.

![SEM photograph of formulation F5](JYPharm-3-189-g015){#F5}

The sphericity factor was obtained in the range 1.00 to 1.09, indicating that the prepared formulations were spherical in nature.

Drug content was measured in order to ascertain that the drug was uniformly distributed in the formulation. One hundred mg of the drug-loaded microparticles were taken in a 100 ml volumetric flask containing 7.4 pH buffer solution, and were shaken for 45 min and then filtered through Whatmann No.1 filter paper. The amount of RNZ present in the buffer solution was determined spectrophotometrically at 270 nm. The percentage of drug loading in the formulations was found to be in the range of 36.35--45.23. The percentage encapsulation efficiency was found to be 65.25--89.66. The results obtained are given in [Table 7](#T7){ref-type="table"}. Formulation F5 showed maximum drug loading when compared to other formulations.

###### 

Drug loading and encapsulation efficiency of prepared microparticles

![](JYPharm-3-189-g016)

*In vitro* release studies were carried out for all formulations in both gastric and intestinal media. For the formulations F1--F10, as shown in [Figure 6](#F6){ref-type="fig"}, it was noticed that the drug release rate decreases with increase in EC concentration. Studies also showed that the drug release rate increases with increase in EU RL 100 concentration. The drug release profile of optimized RNZ microparticle formulations was compared with the marketed formulation of RNZ (Ranexa SR) \[[Figure 7](#F7){ref-type="fig"}\]. Among the prepared formulations the F5 formulation showed good controlled release effect based on release profile, similarity factor, differential factor, model fitting and release kinetics.

![*In vitro* drug release profile of prepared RNZ microparticles' formulations. F1(-▲-), F2(-Δ-), F3(-■-), F4(-□-), F5(-●-), F6(-○-), F7(-♦-), F8(-◊-), F9(-x-), F10(----)](JYPharm-3-189-g017){#F6}

![*In vitro* drug release profile of prepared RNZ microparticles' formulations. F5 (-♦-), F4 (-□-)](JYPharm-3-189-g018){#F7}

From the release studies it was observed that there is no significant release of drug in gastric pH from the microparticles and this indicates that the used polymer blend is gastro-resistant in nature. In intestinal pH, drug was released in a biphasic manner consisting of an initial fast release stage followed by a slow release.

Initial drug release from drug-loaded microparticles in the intestinal environment was associated with initial burst release. The burst release in the intestinal pH might be due to the release of surface-accumulated drug. After the initial burst effect, the subsequent release of the drug was slow and sustained. From the present study, it was observed EC (225:75) in a ratio of (225:75) i.e. a increase in EU concentration and a decrease in EC concentration helps to control the drug release from the particles.

The similarity factor fit the result between 50 and 100. It approached 0 as the dissimilarity of the test and the reference profile increased, whereas it attained 100 when the test and the reference profile were identical. The two profiles were believed to be similar when their *f*~1~ value was between 0 to 15 (3.48 for F5) and their *f*~2~ value was larger than 50 (82.1 for F5), for which the mean deviation over all time points 'n' was less than 10% based on above equation. Formulation 5 showed that it was most similar to the marketed reference standard.

[Table 8](#T8){ref-type="table"} lists the composition of the RNZ microparticles, and expected and experimented values of all the formulations. From the presented results the release in 1h varies in a non-linear fashion and with increase in the amount of EU or decrease in the amount of EC. From the results it was observed that EU had exhibited a considerable effect on the drug release. In contrast, the results of the drug release revealed that release in 8 h varies in linear fashion with increased amount of EU and decreased amount of EC. Time taken for 50% drug release (t50%) varies in a non-linear fashion.

###### 

Formulations, response, and predicted values of RNZ microparticles

![](JYPharm-3-189-g019)

The data of the *in vitro* release studies was fitted into various mathematical models to determine the best-fit model. The results indicated that the best-fit models were the Peppas and Higuchi models. In all the cases the value of intercept, A was found to be less than 0.5. This indicates that the release of the drug from all the formulations followed the Fickian mechanism. The amount of drug released versus the square root of time was plotted. The plot should be linear if the release of the drug from the delivery system is diffusion-controlled. The dissolution graphs were found to be linear and the results inferred that the drug release from the microparticle formulation was by diffusion.

CONCLUSION {#sec1-4}
==========

The objective of this study was to prepare and evaluate microparticles of an EU and EC mixture loaded with RNZ for controlled release by the phase separation method. Spherical discrete microparticles were obtained. The prepared microparticles exhibited good micromeritic properties. From the results of the particle size analysis it was clear that all the process variables were within the limits and the process is reproducible. FT-IR studies indicated that there was no interaction between the drug and the polymers in the prepared microparticles. The DSC thermograms obtained from the pure drug and the formulation showed no significant shift in the endothermic peaks confirming the stability of the drug in the formulation. The *in vitro* drug release studies showed that the release of the drug was found to be diffusion-controlled. Results of dissolution studies for formulation F5 and the marketed product showed that both have nearly similar release profiles. From the results, it can be concluded that the microparticles' formulation is easy to administer, simple, and economical with increased patient compliance. Hence RNZ could be formulated into microparticles as a controlled drug release dosage form by the phase separation method.

These results demonstrate the potential use of EU and EC combinations for fabrication of delivery systems of other water soluble drugs in a controlled manner.
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